How a CEO Pivots Their Company and Career

In this ISSUE

Split Congress to Attack Drug Pricing

Digital Transformation: What's the Cost of Doing Nothing?

The Copay Showdown

The FDA

FDA's $100 Million RWE Project: Making It All It Can Be

FDA's proposal to gather real-world evidence from 10 million individuals could have profound implications, but the Agency needs to take a more expansive view of what RWE can be, writes Paul Glimcher.
... /Read more/

Patient Assistance Centers of Excellence: The Next Generation of Brand Support
Wednesday, November 14^th at 11:00 AM EST

Research & Development

Bridging R&D and IP: Anjum Swaroop, Dr. Reddy's

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks about her journey with the company and about what the future holds for this major US generics player.
... /Read more/

Bringing Intelligence to Drug Discovery The Importance of Contextual Information at All Levels
On Demand

Learn More

Calendar

/ Bio/Pharma Summit on Nurse Educator Programs 11/27 /

/ Early Clinical Development 11/27-11/29 /

/ Partnerships in Clinical Trials Europe 11/27-11/29 /

/ Compliant Patient Support Programs Summit 11/28-11/29 /

/ Digital Therapeutics 12/3-12/4 /

/ Managed Markets Compliance Congress 12/4-12/5 /

How a CEO Pivots Their Company and Career

The Pharm Exec Podcast: Episode 19

Christen and Michelle talk with Mei Mei Hu, CEO of United Neuroscience about how being open to pivoting from your original plan can create a number of opportunities for an executive and their company, as well as how her executive team successfully manages a remote workforce spread across three continents.
... /Read more/

Seizing Opportunities in Japan, the Second Largest Innovation-Driven Pharmaceutical Market
On Demand

Learn more

Drug Development

Stunted Innovation in Drug Development?

Data shows cultural gaps and highlights a C-level fix, writes Meghan Oates-Zalesky.
... /Read more/

Pricing

Is the Price Right? An Overview of US Pricing Strategies

Bruno Delagneau reviews the current landscape for price-setting in the US and suggests that it's time for pharma to change their practices.
... /Read more/

update my profile / advertise with us / print & digital subscribe / visit pharmexec.com